Haryono Andreas, Ramadhiani Risa, Ryanto Gusty Rizky Teguh, Emoto Noriaki
Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Laboratory of Clinical Pharmaceutical Science, Kobe Pharmaceutical University, Kobe 658-8558, Japan.
Biology (Basel). 2022 May 16;11(5):759. doi: 10.3390/biology11050759.
Endothelin was first discovered more than 30 years ago as a potent vasoconstrictor. In subsequent years, three isoforms, two canonical receptors, and two converting enzymes were identified, and their basic functions were elucidated by numerous preclinical and clinical studies. Over the years, the endothelin system has been found to be critical in the pathogenesis of several cardiovascular diseases, including hypertension, pulmonary arterial hypertension, heart failure, and coronary artery disease. In this review, we summarize the current knowledge on endothelin and its role in cardiovascular diseases. Furthermore, we discuss how endothelin-targeting therapies, such as endothelin receptor antagonists, have been employed to treat cardiovascular diseases with varying degrees of success. Lastly, we provide a glimpse of what could be in store for endothelin-targeting treatment options for cardiovascular diseases in the future.
内皮素于30多年前首次被发现,是一种强效血管收缩剂。在随后的几年里,人们鉴定出了三种异构体、两种典型受体和两种转化酶,并通过大量临床前和临床研究阐明了它们的基本功能。多年来,内皮素系统已被发现对包括高血压、肺动脉高压、心力衰竭和冠状动脉疾病在内的几种心血管疾病的发病机制至关重要。在这篇综述中,我们总结了关于内皮素及其在心血管疾病中作用的当前知识。此外,我们讨论了内皮素靶向治疗,如内皮素受体拮抗剂,如何被用于治疗心血管疾病并取得了不同程度的成功。最后,我们简要介绍了未来心血管疾病内皮素靶向治疗方案的前景。